SG3 Management, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
SG3 Management, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2021$194,000
+40.6%
3,7000.0%0.00%0.0%
Q3 2021$138,000
-32.4%
3,700
-26.0%
0.00%
-42.9%
Q2 2021$204,000
-83.4%
5,000
-87.1%
0.01%
-69.6%
Q4 2020$1,230,000
-12.8%
38,680
-29.7%
0.02%
-76.3%
Q2 2020$1,411,00055,0000.10%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2021
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders